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The choice of chemotherapeutic drugs to treat patients with epithelial ovarian cancer has not 
depended on individual patient characteristics.  We have investigated the correlation between in vitro 
chemosensitivity,  as determined by the histoculture drug response assay (HDRA),  and clinical 
responses in epithelial ovarian cancer.  Fresh tissue samples were obtained from 79 patients with epi-
thelial ovarian cancer.  The sensitivity of these samples to 11 chemotherapeutic agents was tested using 
the HDRA method according to established methods,  and we analyzed the results retrospectively.  
HDRA showed that they were more chemosensitive to carboplatin,  topotecan and belotecan,  with 
inhibition rates of 49.2ｵ,  44.7ｵ,  and 39.7ｵ,  respectively,  than to cisplatin,  the traditional drug of 
choice in epithelial ovarian cancer.  Among the 37 patients with FIGO stage Ⅲ/Ⅳ serous adenocarci-
noma who were receiving carboplatin combined with paclitaxel,  those with carboplatin-sensitive 
samples on HDRA had a signiﬁcantly longer median disease-free interval than patients with carbopla-
tin-resistant samples (23.2 vs.  13.8 months,  p＜0.05),  but median overall survival did not diﬀer signiﬁ-
cantly (60.4 vs.  37.3 months,  p＝0.621).  In conclusion,  this study indicates that HDRA could provide 
useful information for designing individual treatment strategies in patients with epithelial ovarian 
cancer.
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varian cancer is the most common cause of 
death among gynecologic malignancies [1].  
Approximately 90ｵ of ovarian cancers are of the 
epithelial type,  and most patients present with 
advanced-stage disease.  The treatment of choice for 
patients with advanced ovarian cancer consists of 
adequate surgical cytoreduction,  followed by plati-
num-based chemotherapy,  which yields initial response 
rates of 70ｵ to 80ｵ,  including a high proportion of 
complete responses.  Most patients,  however,  eventu-
ally relapse and die of chemoresistant disease.  Tumor 
cell sensitivity to chemotherapeutic agents depends on 
various factors,  including cancer cell viability and 
complex genomic alterations.  Usually,  however,  the 
choice of chemotherapeutic drug is based on clinical 
trials that determine whether a drug is eﬀective in 
large numbers of patients.  This approach ignores 
variations in individual patient conditions [2].  To 
improve the outcome in patients with ovarian cancers,  
it is important to select the chemotherapeutic agents 
most eﬀective for each individual patient.
　 Although in vitro methods may accurately predict 
the chemosensitivity of human tumors in vivo [3-5],  
none of these methods has yet been applied clinically 
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because of their technical complexity and the diﬃculty 
of obtaining evaluable tumor samples.  In addition,  
although these methods can exclude ineﬀective drugs,  
they are less useful in the selection of eﬀective drugs 
because true-positive rates tend to be lower than true-
negative rates.  These ﬁndings suggest the need for 
eﬀective drug sensitivity tests that overcome these 
disadvantages.  The histoculture drug response assay 
(HDRA) with the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-di-
phenyltetrazolium bromide (MTT) endpoint may be 
used to detect individual chemosensitivity in many 
types of cancer [6-10].  The HDRA is appropriate for 
the culture of many types of cancer cells because it 
allows these cells to be cultured in their natural 
three-dimensional architecture [10,  11].  Recently,  
HDRA has been reported to be clinically useful in 
patients with breast and gastrointestinal cancers [12,  
13].  HDRA was also reported to be eﬀective in pre-
dicting the response to chemotherapy in patients with 
ovarian cancer; moreover,  using the HDRA to mea-
sure the response to cisplatin may be useful in opti-
mizing cisplatin-based therapy,  including combinations 
with doxorubicin and cyclophosphamide,  for patients 
with ovarian cancer [14].  We therefore used the 
HDRA to assess the sensitivity of epithelial ovarian 
cancer cells to various chemotherapeutic agents,  and 
we evaluated the correlation between HDRA results 
and the clinical responses of patients to carboplatin.
Patients and Methods
　 Patients. Fresh tissue samples were obtained 
from 79 patients with epithelial ovarian cancer who 
were treated at the Asan Medical Center between 
January 2004 and December 2007.  The medical 
records and pathologic reports of these patients were 
reviewed retrospectively.  We performed this retro-
spective study with the approval of the Institutional 
Review Board of Asan Medical Center to protect the 
patientsʼ conﬁdentiality.  The median age of these 79 
patients was 50 years (range: 19-74 years) and the 
median follow-up duration was 28.5 months (range:  
0.7-79.5 months).  Of the 79 patients,  17 (21.5ｵ) had 
the International Federation of Gynecology and 
Obstetrics (FIGO) stageⅠ,  1 (1.3ｵ) had stageⅡ,  
52 (65.8ｵ) had stageⅢ,  and 9 (11.4ｵ) had stageⅣ 
tumors.  Fifty-ﬁve patients (69.6ｵ) had serous adeno-
carcinomas,  6 (7.6ｵ) had mucinous adenocarcinomas,  
and 4 (5.1ｵ) had clear cell carcinomas.  All patients 
underwent surgery,  and 70 (88.6ｵ) received plati-
num-based chemotherapy as an adjuvant treatment,  
including 57 patients treated with carboplatin and 13 
with cisplatin (Table 1).  Recurrence was reported in 
46 patients (58.2ｵ).
　The histoculture drug response assay. HDRA 
procedures were performed as described [10].  Fresh 
tumor tissue samples were obtained from each patient 
and transported to the laboratory at 4℃ in Hankʼs 
balanced salt solution (HBSS; Gibco,  Gaitherburg,  
MD,  USA).  Tumor tissues were cut into approxi-
mately 10-mg pieces,  and viable parts were selected 
based on staining methods.  The tumor tissues were 
placed onto collagen sponge gels (Gel Foam; Pharmacia 
& UpJohn Inc.,  UK) in 24-well plates and incubated 
for 24h in RPMI 1640 medium (Sigma,  St.  Louis,  
MO,  USA) containing 20ｵ fetal calf serum at 37℃ 
with 5ｵ CO2.  The next day,  chemotherapeutic agents 
were added to each well,  and the plates were incu-
bated for 72h.  The concentration of each of the 11 
drugs used in this study was determined in our labora-
tory based on previous determinations of 50ｵ growth 
inhibition of tumor cells (IC50 values): 75µg/mL 
paclitaxel,  50µg/mL carboplatin,  10µg/mL cisplatin,  
75µg/mL docetaxel,  10µg/mL topotecan,  20µg/mL 
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Table 1　 Clinicopathologic characteristics of patients
Characteristic No. of patients
Total no. of patients 79
Median age (years) 50 (19-74)
Median follow-up duration (months) 28.5 (0.7-79.5)
FIGO stage
Ｉ 17
Ⅱ 1
Ⅲ 52
Ⅳ 9
Histology
Serous adenocarcinoma 55
Mucinous adenocarcinoma 6
Clear cell carcinoma 4
Endometrioid adenocarcinoma 2
Others 12
Adjuvant treatment modalities
No adjuvant treatment 7
Carboplatin-based chemotherapy 57
Cisplatin-based chemotherapy 13
Not known 2
belotecan [15],  20µg/mL irinotecan,  250µg/mL 
ifosfamide,  50µg/mL etoposide,  6µg/mL adriamycin,  
and 50µg/mL gemcitabine.  As a control,  each tumor 
tissue sample was cultured with phosphate-buﬀered 
saline (PBS) in the absence of chemotherapeutic 
agents.
　 After the tumor samples were incubated with drugs 
for 3 days,  100µL PBS containing 0.1mg/dL colla-
genase (typeⅠ) and 5mg/dL MTT (Sigma) were added 
to each well,  and the plates were incubated at 37℃ 
for an additional 4h.  The resulting formazan crystals 
were extracted from the wells with dimethyl sulfoxide,  
and the optical density was measured with a plate 
reader (SPECTRA max 340PC,  Molecular Devices) 
at 540nm.  The inhibition rate (IR) was calculated 
using the formula:
IR＝ (1-T/C)×100,  where
T is the mean absorbance of the treated tumor/g
C is the mean absorbance of the control tumor/g.
　 The cut-oﬀ values of the HDRA IR for deciding the 
chemosensitivities of tumor samples to several chemo-
therapeutic agents were not well deﬁned.  We there-
fore determined these cut-oﬀ values by comparing 
HDRA results with clinical outcomes.
　 Assessment of chemosensitivity in the HDRA 
and clinical response. To determine the carbo-
platin IR cut-oﬀ value in the HDRA related to clinical 
prognosis,  we selected patients with stageⅢ or Ⅳ 
epithelial ovarian serous adenocarcinoma who had 
received at least 3 cycles of chemotherapy with carbo-
platin combined with paclitaxel.  Disease-free intervals 
were analyzed in groups of patients divided by IR 
intervals of 10 using multiple comparison tests and 
Cox regression tests.  Clinical responses were evalu-
ated using the Response Evaluation Criteria in Solid 
Tumors (RECIST) criteria [16].  The disease-free 
interval was measured from the pathologic conﬁrma-
tion of epithelial ovarian cancer to documented pro-
gressive disease.  In patients without recurrence,  the 
disease-free interval was deﬁned as the period from 
pathologic diagnosis to last follow-up.  Patients 
responsive to initial carboplatin-based chemotherapy 
and who did not experience a recurrence within 6 
months after ﬁnishing chemotherapy were deﬁned as 
carboplatin-sensitive.  Descriptive statistics were used 
to analyze chemosensitivity in the HDRA and clinical 
characteristics,  and the Kaplan-Meier method was 
used to compare chemosensitivity and clinical outcome.  
Statistical signiﬁcance was deﬁned as p＜0.05.  SPSS 
v15.0 was used for all statistical analyses.
Results
　 The ability of 11 chemotherapeutic agents to 
inhibit the growth of epithelial ovarian cancer tumor 
samples was tested using the HDRA.  The IRs of 
paclitaxel and carboplatin,  the chemotherapeutic agents 
of choice for treating ovarian cancer,  were 32.2ｵ 
and 49.2ｵ,  respectively.  Cisplatin,  a traditional 
platinum agent,  had an IR of 34.7ｵ.  In addition,  2 
topoisomerase I inhibitors,  topotecan and belotecan,  
had high IRs of 44.7ｵ and 39.7ｵ,  respectively 
(Fig.  1).  Chemosensitivities,  however,  did not diﬀer 
by histopathologic type or FIGO stage.
　 Among the 37 patients with FIGO stageⅢ/Ⅳ 
serous adenocarcinoma who were receiving carboplatin 
combined with paclitaxel,  those with carboplatin-sen-
sitive samples on HDRA had a signiﬁcantly longer 
median disease-free interval than those with carbopla-
tin-resistant samples (23.2 vs.  13.8 months,  p＜0.05),  
but the median overall survival did not diﬀer signiﬁ-
cantly between these 2 groups (60.4 vs.  37.3 months,  
p＝0.621).
　 We also assessed the response and prognosis rela-
tive to IRs in the HDRA among the 37 patients with 
stageⅢ/Ⅳ serous epithelial ovarian cancer who had 
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Fig. 1　 Results of in vitro chemosensitivity tests using the HDRA 
in ovarian cancer.  Data are expressed as mean ± standard devia-
tion; (1) TAXOL: paclitaxel,  IR 32.2±17.6 (2) CBP: carboplatin,  
IR 49.2±18.8 (3) CDDP: cisplatin,  IR 34.7±19.6 (4) DTAX:  
docetaxel,  IR 30.4±18.6 (5) TOP: topotecan,  IR 44.7±18.5 (6) 
BEL: belotecan,  IR 39.7±17.8 (7) BLM: bleomycin,  IR 22.1±
16.8 (8) IFS: ifosfamide,  IR 22.1±16.1 (9) VP16: etoposide,  IR 
25.0±12.9 (10) ADR: adriamycin,  IR 30.8±18.9 (11) 
GEM: gemcitabine,  IR 24.0±12.1.
been treated with at least 3 cycles of carboplatin 
chemotherapy.  Multiple comparison tests and Cox 
regression analysis showed that 50µg/mL carboplatin 
was the best cut-oﬀ value for IR in the HDRA (40ｵ) 
that aﬀected the patient disease-free interval,  which 
is the most important clinical outcome.  Patients whose 
samples showed a ＜40ｵ IR in response to 50µg/mL 
carboplatin had a relative risk (RR) of 2.95 (p＜0.05,  
conﬁdence interval (CI) 1.23-7.06) compared with 
patients whose samples showed a ｧ40ｵ IR in response 
to this carboplatin concentration.  Using this cut-oﬀ 
value,  we divided the 37 patients into 2 groups based 
on their sensitivity or resistance to carboplatin in the 
HDRA,  with 22 patients included in the carboplatin-
sensitive group and 15 in the carboplatin-resistant 
group.  The 2 groups had similar clinical and patho-
logical characteristics except for their chemosensitiv-
ity to carboplatin (Table 2),  and their response rates 
based on RECIST criteria were similar (93.3ｵ 
(14/15) vs.  90.9ｵ (20/22),  p＝0.651) (Table 3).  The 
2 groups also showed similar carboplatin-sensitivity in 
clinical outcomes (p＝0. 157) (Table 3).  The median 
disease-free interval was 23.2 months (range,  6.3-
55.3 months) in carboplatin-sensitive patients and 13.8 
months (range,  4.9-35.6 months) in carboplatin-resis-
tant patients (p＜0.05) (Fig.  2).  The median overall 
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Table 2　 Comparison of the clinicopathologic characteristics of patients with carboplatin-sensitive and -resistant tumors in the HDRA
Carboplatin-Sensitive
(n＝22)
Carboplatin-Resistant
(n＝15) p value
Median age (years) 49 (25-73) 53 (30-74) 0.154†
Median follow-up duration (months) 37.8 (6.3-64.7) 28.0 (7.7-79.5) 0.085†
Inhibition rate to carboplatin 57.3±14.2 28.7±8.5 ＜0.000†
FIGO stage 0.951‡
　ⅢB 2 1
　ⅢC 12 8
　Ⅳ 8 6
Histology －
　Serous adenocarcinoma 22 15
Residual tumor 0.785‡
　＜1cm 17 11
　ｧ1cm 5 4
†Mann-Whitney test
‡Chi-squared test
Table 3　 Comparison of clinical responses and survival between patients with carboplatin-sensitive and -resistant tumors in the HDRA
Carboplatin-Sensitive
(n＝22)
Carboplatin-Resistant
(n＝15) p value
Clinical Response 0.651†
　Complete remission 17 13
　Partial response 3 1
　Stable disease 1 1
　Progressive disease 1 0
Carboplatin-sensitivity in the clinical outcome 0.157†
　Sensitive 20 (90.9%) 11 (73.3%)
　Resistant 2 (9.1%) 4 (26.7%)
Disease free interval (months)＊ 23.2 (6.3-55.3) 13.8 (4.9-35.6) ＜0.05‡
Overall survival (months)＊ 60.4 (6.3-64.7) 37.3 (7.7-79.5) 0.621‡
†Chi-squared test
‡Kaplan-Meier test
＊Median (range)
survival of these 2 groups,  however,  did not diﬀer 
signiﬁcantly (60.4 vs.  37.3 months,  p＝0.621) (Fig.  3).  
Clinical outcomes were also not dependent on the use 
of other chemotherapeutic agents,  including paclitaxel.
Discussion
　 Chemosensitivity tests can be performed in vivo 
using animals and in vitro using histoculture or cell 
culture techniques.  Several in vitro and in vivo chemo-
sensitivity assays have been developed to predict 
tumor responsiveness to a clinically administered drug 
and to improve the eﬀectiveness of treatment and 
prognosis.  Currently available,  clinically applicable 
chemosensitivity tests include the MTT assay [17],  
the 3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymeth-
oxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt 
(MTS) assay [18],  the HDRA [4-8],  and the colla-
gen gel droplet-embedded culture drug sensitivity test 
[19,  20].
　 The monolayer culture MTT assay is based on the 
reduction of MTT by mitochondrial succinic dehydro-
genase in living cells; this reaction yields the colored 
compound formazan,  which is measured optically using 
a plate reader.  This enzymatic receptor assay can 
evaluate drug sensitivity rapidly and simply,  and is 
accurate in more than 90ｵ of samples [13].  The 
MTT assay has been used in the screening of chemo-
therapeutic agents at the National Cancer Institute 
since 1991.  The MTS assay is a modiﬁed,  improved 
version of the MTT assay.  However,  monolayer cul-
ture MTT and MTS assays eliminate cell-cell contact 
because the cancer cells are assessed as single-cell 
suspensions [7]; thus,  these tests are signiﬁcantly 
inﬂuenced by the presence of contaminating ﬁbroblasts,  
and the viability of tumor cells decreases during cul-
ture under control conditions.  Chemosensitivity assays 
using three-dimensional HDRA,  which utilize a soft 
agar substrate,  may more accurately mimic the in vivo 
response.  The HDRA is a robust assay for a number 
of cancers,  with an evaluation rate of 98.8ｵ,  a mean 
sensitivity of nearly 100ｵ,  a speciﬁcity of 70-90ｵ,  
and a clinical correlation of 80-90ｵ [8,  12].  These 
high rates are due,  at least in part,  to the mainte-
nance of the three-dimensional tissue architecture in 
the HDRA.  Correlations between survival and in vitro 
chemosensitivity have been observed in patients with 
gastrointestinal cancer and in those with ovarian can-
cer [5,  21].  We previously reported that the HDRA 
may provide information useful for designing individu-
alized treatments for patients with uterine cervical 
cancer [22].  To date,  however,  only a few retro-
spective studies have shown correlations between 
survival beneﬁts in cancer patients and chemosensitiv-
ity assays.  This is especially true for ovarian cancer,  
for which there have been few reports on chemosensi-
tivity using MTT or MTS assays.
　 The extreme drug resistance (EDR) assay may also 
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Fig. 3　 Kaplan-Meier survival curves showing overall survival 
(OS) of patients sensitive (n＝22) and resistant (n＝15) to carbo-
platin in the HDRA (n＝15).
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Fig. 2　 Kaplan-Meier survival curves showing disease-free inter-
vals (DFI) of patients sensitive (n＝22) and resistant (n＝15) to 
carboplatin in the HDRA.
be used to guide therapeutic strategies.  For example,  
in 79 patients with advanced ovarian cancer,  the 
median progression-free survival was 6 months for 
patients with EDR to platinum,  compared with 24 
months for patients sensitive to platinum (RR 3.78,  
CI 1.82-7.83) in multivariate analysis [23].  The 
estimated overall 5-year survival rates of these 2 
groups were 19ｵ and 68ｵ,  respectively (RR 2.32,  
CI 1.06-5.07).  Moreover,  in vitro drug resistance at 
recurrence was not inﬂuenced signiﬁcantly by therapy 
[24],  suggesting that assay results at diagnosis may 
be used to guide treatment modalities at recurrence.
　 The combination of paclitaxel and a platinum com-
pound (usually carboplatin or cisplatin) has been pre-
ferred in the primary treatment of women with 
advanced epithelial ovarian cancer,  with response 
rates as high as 75ｵ [25,  26].  However,  although 
chemotherapy has increased survival duration,  most 
women suﬀer from recurrent disease,  and only 20ｵ 
to 25ｵ remain alive at 5 years.  The preferred agents 
for treating tumor recurrences include carboplatin,  
cisplatin,  paclitaxel,  gemcitabine,  liposomal doxoru-
bicin and topotecan.  Among the cytotoxic alternatives 
are altretamine,  capecitabine,  cyclophosphamide,  
docetaxel,  etoposide,  ifosfamide,  irinotecan,  mel-
phalan,  oxaliplatin,  and vinorelbine.  Except for cis-
platin or carboplatin,  as monotherapy or combined 
with paclitaxel,  most regimens lack a uniform National 
Comprehensive Cancer Network consensus based on 
primary evidence,  including clinical experience.  We 
found that the IRs of topotecan and belotecan were 
higher than that of cisplatin,  and that the IR of the 
cisplatin and paclitaxel combination was somewhat 
lower than expected.  Similarly,  MTT assays of 32 
clinical samples of tumor and ascites cells showed that 
these cells were most sensitive to topotecan [27].
　 Chemosensitivity testing in patients with epithelial 
ovarian cancer should be performed to determine 
patient prognosis and to select proper chemotherapeu-
tic agents.  When ovarian cancer samples were assayed 
in vitro for their sensitivity to cisplatin using the 
HDRA and compared with clinical response and sur-
vival,  using a cut-oﬀ value set at a 50ｵ inhibitory 
concentration of 25µg/mL,  the 5-year survival rate 
was found to be signiﬁcantly higher in patients with 
chemosensitive tumors than in those with chemoresis-
tant tumors,  and the accuracy of the assay was 82.8ｵ 
(24/29) [28].  As chemosensitivity to cisplatin increased,  
the number of apoptotic cells also increased.  In com-
parison,  we found that when we assessed 37 patients 
with FIGO stageⅢ/Ⅳ serous adenocarcinoma who had 
received at least 3 cycles of chemotherapy with carbo-
platin plus paclitaxel,  the median disease-free interval 
was signiﬁcantly higher in patients with carboplatin-
sensitive samples than in those with carboplatin-
resistant samples (23.2 vs.  13.8 months,  p＜0.05),  
although their response rates and overall survival did 
not diﬀer signiﬁcantly.  This result shows the critical 
role of HDRA to reﬂect in vivo chemosensitivity to 
carboplatin,  since the time of relapse after chemo-
therapy with carboplatin plus paclitaxel was later in 
the carboplatin-sensitive group as determined by 
HDRA.  Furthermore,  although overall survival was 
not diﬀerent according to the HDRA result,  a relation 
between HDRA and survival might be revealed if the 
period of observation is extended.
　 Ideally,  chemotherapy should be based on individ-
ual cellular and genetic diﬀerences.  Chemosensitivity 
tests,  including the HDRA,  enable chemotherapy 
regimens to be individualized.  These tests,  however,  
are not widely accepted in the treatment of ovarian 
cancer because the available clinical trial data are 
insuﬃcient,  although some in vitro chemosensitivity 
assays are restricted for use in the United States,  
Germany and Italy.  The HDRA can analyze chemo-
sensitivity and provide information that can guide 
primary treatment and therapeutic strategies at 
relapse in patients with ovarian cancer.  HDRA results 
can help select the appropriate chemotherapeutic 
agents to improve clinical outcomes for individual 
patients.  Large,  randomized,  controlled trials are 
required,  however,  to determine the clinical beneﬁts 
of the HDRA in patients with epithelial ovarian cancer.
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